Manufacturers Novo Nordisk and Eli Lilly are facing lawsuits over claims that popular weight loss drugs Ozempic and Mounjaro cause severe stomach paralysis. A Louisiana woman alleges the drugs led to violent illness and emergency room visits. Despite these legal challenges, demand for GLP-1 agonists remains high, even as some insurance systems, like the University of Texas, begin to limit coverage.
